Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it. The COVID-19 virus has been named “SARS-CoV-2” (severe acute respiratory syndrome coronavirus 2) and the disease it causes has been named “Coronavirus Disease 2019” (COVID-19). The outbreak of the respiratory disease was first detected […]Read More
Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it. The COVID-19 virus has been named “SARS-CoV-2” (severe acute respiratory syndrome coronavirus 2) and the disease it causes has been named “Coronavirus Disease 2019” (COVID-19). The outbreak of the respiratory disease was first detected […]Read More
1. I-Mab to Initiate the Development of TJM2 for Treating Cytokine Release Syndrome Associated with COVID-19 Published: Mar 13, 2020 | Tags: I-Mab, Initiate, Development, TJM2, Treating, Cytokine Release Syndrome, COVID-19 2. EMD Serono and Pfizer to Terminate P-III JAVELIN Head and Neck 100 Study Evaluating Bavencio + CRT for Squamous Cell Carcinoma of the Head […]Read More
Shots: Atomwise to receive ~ $1.08B as an up front, milestones and royalties on the success of the programs and will utilize its AI technology to evaluate Pellino E3 ubiquitin ligase and other targets nominated by Bridge The collaboration will discover and develop up to 13 small molecule programs across multiple therapeutic areas including inflammatory […]Read More
1. Sage Therapeutics Reports Results of SAGE-217 in P-III MOUNTAIN Study for Major Depressive Disorders Published: Dec 05, 2019 | Tags: Sage Therapeutics, Reports, Results, SAGE-217, P-III, MOUNTAIN Study, Major Depressive Disorders 2. UCB Reports Results of Bimekizumab in P-III BE SURE Study for Moderate-To-Severe Chronic Plaque Psoriasis Published: Dec 06, 2019 | Tags: UCB, […]Read More
Shots: Joint Venture will combine StemoniX’s human microOrgan platform with Atomwise’s AI technology to allow the rapid discovery and development of novel therapies, initially targeting Rett syndrome Atomwise will utilize its AI technology for identifying potent and selective binders for protein targeting Rett syndrome while StemoniX will test the compounds on its human microBrain 3D […]Read More
Shots: Atomwise to receive technology access fees, option exercise fees, royalties, and income-based on sublicensing or sale of assets leading to a total deal value of ~$1.5B. The companies will develop therapies for up to eleven target protein in multiple therapeutic areas The agreement involves the collaboration of a scientific team of both the companies, […]Read More
Shots: Pfizer will pay access fee for using Atomwise’s AI technology with success-based payments for each target protein selected, while Atomwise will computationally analyse various small molecules for each of Pfizer’s identified target proteins Additionally, Atomwise medicinal and computational chemistry team will work collaboratively with Pfizer scientists to identify potency and chemical properties of the […]Read More
Copyright ©2020 PharmaShots | Powered by Octavus Consulting
